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Introduction
Infantile spasms (IS) are among the most catastrophic myoclonic epilepsies of 
infancy (1).
Incidence of IS varies from 0.2 to 0.6 per 100 child, and the peak onset age of the 
epileptic syndrome is 3 to 7 months. The spasms are bilateral, causing symmetric 
sudden contractions of neck, trunk, and extremities, and they may be of flexor, 
extensor or mixed types. Hypsarrhythmia pattern is seen in electroencephalography 
of such patients, which is composed of a chaotic, bilaterally asynchronous high-
voltage polyspike and slow wave discharges interspersed with multifocal spikes 
and slow waves (2,3). 




Infantile spasms (IS) are among the most catastrophic epileptic syndromes 
of infancy. The purpose of this study was to compare efficacy and safety of 
topiramate (TPM) and nitrazepam (NZP) as first-line drugs in the treatment of 
IS.
Materials & Methods
In a parallel single-blinded randomized clinical trial, 50 patients with IS referred 
to Pediatric Neurology Clinic of Shahid Sadoughi University of Medical 
Sciences, Yazd, Iran, were evaluated from September 2008 to March 2010. 
Patients were randomly assigned to two groups to be treated with TPM or with 
NZP for 6 months. The primary endpoint was efficacy in cessation of all spasms 
or reduction of more than 50% in weekly seizure frequency, which was evaluated 
before and 6 months after the drug use. Secondary outcome was clinical side-
effects of the drugs. 
Results
Twenty boys (40%) and 30 girls (60%) with the mean age of 9.4±3.8 months 
were evaluated. Cessation of all spasms occurred in 12 (48%) infants in TPM 
group and 4(16%) in NZP group. Eight (32%) children in TPM group and 7 
(28%) in NZP group had more than 50% reduction in spasms frequency. So, 
TPM was more effective. Side effects were seen in 32% of TPM and in 36% of 
NZP groups.
Conclusion
Topiramate is an effective and safe drug, which might be considered as the first-
line drug for the treatment of ISs. 
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IS treatments. Its anticonvulsant effect is based on the 
following mechanisms: 
a) Blocking of voltage-dependent Na channels; 
b) Enhancing the inhibitory activity of GABA;
c) Inhibition of excitatory neurotransmission by 
blocking Kainate /AMP glutamate receptors;
d) Inhibition of erythrocyte carbonic anhydrase (2,7, 
9-16). 
There is no consensus on mean daily dose of TPM (10), 
and up to 35 mg/kg/day has been used in IS (7,10,11,16) 
but maximum dose of 12 mg/kg/day is more effective 
and safer (13,14,17). 
The purpose of this study was to compare clinical 
efficacy and safety of TPM and NZP as first-line drugs 
in the control of infantile spasms in Yazd, Iran. 
Materials & Methods 
A randomized single–blind clinical, open-label, parallel 
group study was conducted on patients with ISs who 
were referred to Pediatric Neurology Clinic of Shahid 
Sadoughi University of Medical Sciences, Yazd, Iran, 
from September 2008 to March 2010. 
Eligible participants included two months to two 
years old children who had ISs, and did not use any 
antiepileptic drugs, ACTH and/ or oral corticosteroids. 
Exclusion criteria consisted of presence of metabolic 
acidosis, kidney dysfunction, renal stone, and those 
who had not completed 6 months of treatment period.
The diagnostic criteria for the IS in this study were 
based on International League against Epilepsy (ILAE), 
which were classified and done with two groups: 
symptomatic and cryptogenic (4). 
The developmental status of the patients was assessed 
by a pediatric neurologist according to Denver II 
Developmental Screening test.
equal randomization was used in this trial, and the 
allocation ratio was 1:1 for the two groups.
Simple randomization was done using a computer 
generated random number list, which was prepared by 
an investigator with no clinical involvement in the trial, 
and no restriction was exerted. First of all, a research 
resident obtained parents’ consent and called a person 
who was independent of the recruitment process for 
allocation consignment.
The trial adhered to established procedures to maintain 
Etiologic classification of infantile spasms is as follows:
1. Symptomatic: with identifiable prenatal, perinatal, 
and postnatal causes with developmental delay at the 
time of presentation 
2. Cryptogenic: Unknown underlying cause, normal 
development at the onset of spasms, normal neurological 
exam and neuroimaging and no abnormalities in 
metabolic evaluation. 
3. Idiopathic: Pure functional cerebral dysfunction 
with complete recovery, no residual dysfunction, 
normal neurodevelopment, normal neuroimaging, and 
normal etiologic evaluation. This class is based on final 
outcome and cannot be certainly confirmed according 
to the history and presenting symptoms. The terms 
idiopathic and cryptogenic have been synonymously 
used in many studies (2,4-6). 
Since early control of spasms may improve prognosis 
and is accompanied by a higher chance for normal 
developmental outcome, treatment should be begun 
immediately (5-7). 
There is no agreement on the first choice of the drug 
for treatment of IS and no single treatment regimen 
could be considered superior to others. ACTH or oral 
corticosteroids, pyridoxine, vigabatrin, and other drugs 
such as valproic acid, nitrazepam (NZP), topiramate 
(TPM), zonisamide, lamotrigine, levetiracetam, 
felbamate, ganaxolone, liposteroid, thyrotropin-
releasing hormone, intravenous immunoglobulin, 
and also ketogenic diet might be used in treatment of 
spasms as first or second line drugs (2,7). 
ACTH is expensive and hard to obtain in Iran and 
it has many side-effects, including hypertension, 
infection, electrolyte abnormalities, hyperglycemia, 
weight changes, brain shrinkage, sleep and behavioral 
abnormalities, subdural hematoma/effusion, 
development of new seizure types, and even death 
(2,7). Irreversible visual field defect was seen in 30 to 
50% of children who were treated with vigabatrin (8). 
It is difficult to recommend for treatment of IS in the 
absence of comparative trials. So, new antiepileptic 
drugs with greater efficacy and fewer side-effects are 
fiercely needed.
TPM is one such an agent, and it may also be used 
as a second-line agent in treatment of IS of tuberous 
sclerosis, and as a first-line agent for other symptomatic 
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separation between the persons who took outcome 
assessment and the staff who delivered the intervention. 
The drug which was packaged and labeled according 
to a medication code schedule generated before the 
trial, was delivered by the nurses of the clinic. Inside of 
all packages, amount of the drug in one tablet and the 
dosage were written. After opening the packages, drug 
dosage was determined by pediatric neurologist based 
on each child’s weight. 
Primary and secondary outcomes were assessed by a 
research resident who was not informed of the drug 
group assignment. Investigators, staff, and participants 
were all kept masked to outcome measurements and 
trial results.
Informed consent was taken from the patients’ parents, 
and the study was approved by the Ethics Committee 
of Shahid Sadoughi University of Medical Sciences, 
Yazd, Iran.
Sample size based on Z formula and confidence 
interval of 95% with 80% power, type one error of 
5%, good response (more than 50% decrease in weekly 
seizure frequency during the follow-up period) of 85% 
for TPM treatment in another study (18), and an effect 
size (difference in frequency of good response between 
the two groups) of 40% for the primary efficacy end 
point, was assessed in 22 patients per group. For more 
accuracy, total sample size was determined to be 50 
children.
After evaluation for inclusion and exclusion criteria, 
eligible patients were distributed into two groups. In 
group one, 25 infants were treated with TPM and in 
group two, 25 patients were treated with NZP.
In both groups, the drugs were administered orally in 
two divided doses and were started with lowest dosage 
to minimize side effects and then, dosage was increased 
to maximum in a weekly period or to a dosage which 
controlled seizures in a four-week period as follows: 3, 
6, 9, 12 mg/kg/day in patients who took TPM and 0.5, 
0.7, 0.9, 1 mg/kg/day in those for whom NZP was used.
During the treatment period, patients were followed 
up by a pediatric resident of research and in monthly 
consecutive visits of the patients in the Pediatric 
Neurology Clinic of Shahid Sadoughi University of 
Medical Sciences, Yazd, Iran, clinical information 
about seizure frequency and the drugs’ side-effects 
were obtained by interview with the patients’ parents, 
and information of physical examination data which 
were recorded on questionnaires. 
At the end of the 6-month follow up period, drug 
efficacy and safety were evaluated. Weekly seizure 
frequency was compared with its related number, before 
and 6 months after the drug use, and the following 
classification was done: 
1. Seizure-free: all the spasms stopped
2. Improved: more than 50% reduction in spasms 
frequency
3. Unchanged: no notable changes was seen in spasms 
frequency
4. Worsened: spasms frequency increased more than 
25%
Cessation of all spasms or more than 50% of reduction 
in weekly seizure frequency was considered as effective 
and good response.
Video–EEG monitoring facilities were not available in 
our city and cessation of clinical seizures was indicative 
of successful management of IS. 
Primary endpoint was efficacy in cessation of all 
seizures or reduction of more than 50% in weekly 
seizure frequency which was evaluated before and 6 
months after drug use. 
Secondary outcome was clinical side-effects of the 
drugs in the duration of treatment. 
The data were analyzed using SPSS statistical software 
(version 15). Chi-square test or Fisher’s exact test were 
used for data analysis of qualitative variables, and 
mean values were compared using independent t-test. 
Differences were considered significant at p-values of 
less than 0.05.
An iInformed consent was taken from the patients’ 
parents. The study was approved by the Ethics 
Committee of Shahid Sadoughi University of Medical 
Sciences, Yazd, Iran.
This study is registered in Iranian clinical trials with 
registration number IRCT138808052639N1. The 
researchers got no support from the drugs company. 
The design and conduct of this trial were straightforward, 
and we did not have any losses to follow-up or 
exclusions.
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15Iran J Child Neurol. 2014 Winter Vol 8 No 1 
hematologic abnormality, hepatotoxicity, and 
nephrotoxicity were seen in the two groups.
Clinical side effects were seen in 32% (N=8) of the 
patients in the TPM group (lethargy in three, hypotonia 
in two, hyperthermia in two, anorexia and weight loss 
in one), and in 36% (N=9) of NZP group (sialorrhea 
in four, and lethargy in three, hypotonia in one and 
anorexia and weight loss in one). No statistically 
significant differences were seen from viewpoint of 
safety between the two drugs (p=0.76).
All side effects disappeared in one or two weeks and 
treatment was stopped in none of patients who suffered 
from them.
Discussion
In this study, 86% of patients had symptomatic IS 
among whom inborn error of metabolism was the most 
common cause.
In a study Thailand, 45.8% of patients had symptomatic 
and the most common etiology in symptomatic cases 
was hypoxic ischemic encephalopathy (19).
In karvelas et al study, 63% had symptomatic IS, and 
cortical dysgenesia was the most frequent cause (20). 
In a study in Taiwan, 80% of patients had symptomatic 
IS, and tuberous sclerosis, asphyxia, CNS malformation 
were the most common causes (21) and in another 
study, 70% were symptomatic and brain malformations 
and tuberous sclerosis were seen in 35% of patients 
(22). 
In Zagreb, 81.2% had symptomatic IS, and hypoxic-
ischemic encephalopathy was the most common 
etiologic factor (2) and 84% were symptomatic in 
Peltzer et al.’s study (11). 
In the present study, 80% of patients had hypsarrhythmia 
pattern in EEG. Based on pediatric neurology textbook, 
hypsarrhythmia may be seen in 66% of patients and 
it is most obvious in non-rapid eye movement (non- 
REM) sleep (3). This EEG pattern appears after 3-4 
months of age and may only be present periodically 
and may change or even be resolved by the passage 
of time. Moreover, during REM sleep and immediately 
after arousal from REM or non-REM sleep, EEG can 
be normal for up to several minutes (2,3). 
In this study, good response to drugs was not different 
in symptomatic and cryptogenic IS, which is not in 
Results
Twenty boys (40%) and 30 girls (60%) with the mean 
age of 9.4±3.8 months (range=3-20 months) were 
evaluated. Symptomatic IS was seen in 43 (86%) 
patients.
Onset age of seizures was 4.92±3.2 months in 
symptomatic IS and 7.52±2.4 months in cryptogenic 
IS. (p=0.04)
Forty-three children (86%) had neurodevelopmental 
delay, and family history of epilepsy was positive in 
14% (N=7) of them. EEG showed hypsarrhythmia in 
40 (80%) children.
Neuroimaging results were normal in 18 (36%) 
children, and abnormal results were brain atrophy in 20 
(40%), intracranial calcification in 6 (12%), structural 
CNS dysgenesia in 5 (10%), and hydrocephaly in one 
of patients (2%). 
From viewpoint of spasms types, 18 patients (36%) had 
mixed, 17 (34%) had flexor, and 15 showed extensor 
(30%). Comparison of some clinical and paraclinical 
characteristics of patients are shown in Table 1, which 
indicates that sex distribution, type of IS, positive 
family history of epilepsy, etiologic class of IS, EEG 
and neuroimaging results, mean of age, age of seizure 
onset, and number of spasms clusters per week were 
not statistically significantly different between the two 
groups. 
Results of efficacy analysis are illustrated in Table 2, 
which indicate that TPM was more effective in the 
control of spasms. 
After 6 months of treatment, good response (stopping 
of all seizures or more than 50% reduction in weekly 
seizure frequency) was seen in 20 infants (80%) of 
TPM group (95% confidence interval: 0.64-0.96), and 
in 11 patients (44%) of NZP group (95% confidence 
interval: 0.24-0.63). Therefore, TPM was significantly 
more effective (p=0.009). 
Frequency distribution of good response based on 
etiologic class of IS and EEG and neuroimaging 
results is shown in Table 3, which indicates that no 
statistically significant differences were seen from 
these viewpoints.
Mean dose of TPM for seizure control was 6.9±3.4 mg/
kg/day, and it was 0.7±0.3 mg/kg/day for NZP. 
No serious paraclinical adverse events, such as 
Topiramate in infantile spasms 
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accordance with other studies (6,7,11). 
In the present study, control of all spasms by TPM 
treatment was seen in 48% of patients. However, in 
other studies, this rate varied between 16.7% and 
57.4% (10-16,20).
In the present study, more than 50% of reduction in 
seizure frequency was seen in 32% of children with 
TPM treatment, But the rate had been 33% (15), 36% 
(16), 47% (13), and 85% (18) in other studies. 
Possible explanations for these discrepancies are 
differences in sample size, duration of treatment, 
selection method of patients, and dosage of the drug.
Dose of TPM was 3-12 mg/kg/day in this study, while 
in other studies 25 mg/kg/day (16), 3.57-20 mg/kg/
day(12), 1-12 mg/kg/day (14), 3-27 mg/kg/day (15), 
and 1-10 mg/kg/day (24) of the drug had been used. 
In our study, the mean dose of TPM for seizure control 
was 6.9±3.4 mg/kg/day, which is almost similar to a 
Taiwanese study on 13 children, in whom 7.35±4.9 
mg/kg/day of the drug was used. (18) 
In this study, TPM adverse effects were seen in 32% 
of children, and lethargy was the most common side-
effect.
TPM may induce metabolic acidosis, especially in 
patients with renal diseases or in those who are on a 
ketogenic diet or zonisamide (9).
In Mikaeloff et al.’s study, the most common adverse 
effects were neurobehavioral problems (drowsiness, 
fatigue, and hyperactivity) and gastrointestinal 
disorders (anorexia and loss of appetite) (10).
In Pletzer et al. study, 10.5% of patients (2 out of 19) 
showed side-effects, such as appetite loss, tremors, and 
lethargy (11). 
In Zou et al. studies in china, 38.8% had adverse effects, 
most common of which were anorexia and somnolence 
(12).
In Korinthenberg et al.’s study in Germany, adverse 
effects were seen in 25% of patients, and sedation, loss 
of appetite, weight loss, and metabolic acidosis were 
the most common side-effects (13). 
In Hosain et al.’s study, irritability was the most 
common side-effect (15). 
In a study by Grosso et al., adverse effects, including 
weight loss, hyperthermia, sedation, and nervousness 
were seen in 58% of children, and the majority of the 
side-effects then disappeared after slow titration or 
decrease of drug dose (25).
In this study, control of all spasms and more than 50% 
of reduction in seizure frequency with NZP treatment 
was seen in 16% and 28% of patients, respectively, and 
adverse effects were seen in 36% of children, of which 
sialorrhea was the most common side-effect.
In a study in Thailand, effectiveness of sodium 
valproate with or without NZP or clonazepam was 
evaluated in treatment of IS, and they concluded that 
sodium valproate should be used concomitantly with 
benzodiazepines, especially clonazepam (19). 
In Capovilla et al.’s study, three cases with West 
syndrome were treated with NZP in dose of 0.7-1.5 
mg/kg/day. They were evaluated 6 months after the 
discontinuation of the drug, and no cases had recurrence 
of spasms (26). 
In an open label study, 20 children with medically 
refractory infantile spasms or Lennox-Gastaut 
syndrome were treated with NZP in dose of 0.5-3.5 
mg/kg/day. Control of all seizures and more than 50% 
reduction in seizure frequency were respectively seen 
in 25% and 35% of them, and side-effects were oral 
hypersecretion in 60% and sedation in 30% (27). 
In a study on evaluation of the effectiveness of NZP 
in Lennox-Gastaut Syndrome, the most common side-
effects were drooling in 60% and sedation in 40% of 
their patients (28). 
Sudden death and higher mortality were reported 
in epileptic children who received NZP (29), and 
tolerance to drug and significant adverse effects of 
NZP has deterred its more use (30). 
In conclusion, training of parents and children health 
care providers for early reference, diagnosis, and 
treatment of ISs is necessary. TPM is an effective 
and safe drug in treatment of ISs, which should be 
considered as first line of treatment.
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Table1. Comparison of Clinical and Paraclinical Characteristics of Patients In Both Groups
Data Topiramate Nitrazepam p-value
Sex
Female 13 17
0 . 2 4 8
Male 12 8






















Tuberous sclerosis 1 2
0.22
Inborn error of metabolism 5 6
Chromosomal & Genetic syndrome 0 3
CNS dysgenesia 5 3
Congenital infections 3 2
Birth asphyxia 4 3
Others 5 1
Cryptogenic 2 5
Age in months (mean±SD) 9.01±3.96 9.82±3.76 0.491
Age of seizure onset in months (mean±SD) 5.39±2.97 5.22±3.55 0.854
Clusters number in a week (mean±SD) 35.16±28.27 26.16±20.89 0.238
Table 2. Efficacy Results of The Two Drugs After Six Months of Treatment
Drug 
 Response 
Topiramate Nitrazepam Total P-value
Number Percent Number Percent Number Percent
0.03
Seizure free 12 48 4 16 16 32
Improved 8 32 7 28 15 30
Unchanged 4 16 13 52 17 34
Worsened 1 4 1 4 2 4
Total 25 100 25 100 50 100
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